These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 33522861)
1. Gene-Targeted Therapies and Palliative Care in Children with Spinal Muscular Atrophy Type I: No Intrinsic Contradiction. von der Hagen M; Nolte-Buchholtz S; Janisch M; Pietz J; Blankenburg M; Ziegler A J Palliat Med; 2021 Feb; 24(2):162-163. PubMed ID: 33522861 [No Abstract] [Full Text] [Related]
2. [Beyond type I spinal atrophy]. Mastella C Assist Inferm Ric; 1999; 18(4):240-6. PubMed ID: 10833298 [No Abstract] [Full Text] [Related]
3. Gene replacement therapy for spinal muscular atrophy unmasking occult hepatitis C in a pediatric patient. Lakhotia A; Turek G; Green J; Khan M Muscle Nerve; 2022 Jan; 65(1):E2-E3. PubMed ID: 34644404 [No Abstract] [Full Text] [Related]
4. Guidance on Gene Replacement Therapy in Spinal Muscular Atrophy: A Canadian Perspective. Oskoui M; Gonorazky H; McMillan HJ; Dowling JJ; Amin R; Gagnon C; Selby K Can J Neurol Sci; 2022 May; 49(3):398-401. PubMed ID: 34082851 [No Abstract] [Full Text] [Related]
5. [Human leukocyte antigens in children with spinal muscular atrophy]. Májský A; Süssová J; Nevsímal O Cesk Neurol Neurochir; 1987 Sep; 50(5):304-9. PubMed ID: 3664731 [No Abstract] [Full Text] [Related]
6. Ethical aspects in the care of a child with infantile spinal muscular atrophy (SMA). Chabrol B; Desguerre I Arch Pediatr; 2020 Dec; 27(7S):7S50-7S53. PubMed ID: 33357599 [TBL] [Abstract][Full Text] [Related]
7. Paradigm shift in the era of disease-modifying therapies for Spinal Muscular Atrophy type 1: respiratory challenges and opportunities. Xiao L; Chiang J; Amin R Sleep Med; 2021 Oct; 86():113-115. PubMed ID: 34253462 [No Abstract] [Full Text] [Related]
8. Yeo and Darras: Extraneuronal Phenotypes of Spinal Muscular Atrophy. Yeo CJJ; Darras BT Ann Neurol; 2021 Jan; 89(1):24-26. PubMed ID: 33051879 [No Abstract] [Full Text] [Related]
9. Effect on maximal mouth opening in children with spinal muscular atrophy treated with onasemnogene abeparvovec. Beri N; Kapoor L; Parashar D; Mundada V Arch Dis Child; 2023 Oct; 108(10):866-867. PubMed ID: 37553206 [No Abstract] [Full Text] [Related]
15. Disease Burden in Children With Spinal Muscular Atrophy: Results From a Large Cross-Sectional Study. Rosero S; Weinstein J; Seabury J; Zizzi C; Wagner E; Varma A; Heatwole J; Alexandrou D; Ms ND; Johnson BA; Heatwole C J Child Neurol; 2023 Feb; 38(1-2):52-63. PubMed ID: 36537125 [No Abstract] [Full Text] [Related]
16. [The spectrum of spinal muscular atrophies: a population study]. Rudenskaia GE; Mamedova RA Zh Nevrol Psikhiatr Im S S Korsakova; 1997; 97(8):22-5. PubMed ID: 9343477 [TBL] [Abstract][Full Text] [Related]